

AKYNZEO® Capsules Billing & Coding Guide

This document provides general billing and coding information for AKYNZEO® capsules. Please check with the payer to verify coding or special billing requirements. Correct coding is the responsibility of the provider submitting a claim for the item or service.

International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM)

Diagnosis Codes

Providers should use current ICD-10-CM diagnosis codes to report a patient's diagnosis on claim submissions. Below is a list of ICD-10-CM codes that may be reasonably related to a diagnosis within the product's approved label. Other codes may be appropriate.

Diagnosis Code	Description
R11.2	Nausea with vomiting, unspecified
R11.0	Nausea
R11.10	Vomiting, unspecified
R11.11	Vomiting without nausea
R11.12	Projectile vomiting

Please see FDA-approved indications for AKYNZEO® and check with the payer to verify coding or special billing requirements.

INDICATION

AKYNZEO (netupitant/palonosetron) capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

AKYNZEO (fosnetupitant/palonosetron) for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Limitations of Use

AKYNZEO for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT₃) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Please see Important Safety Information on the reverse.

For more information about AKYNZEO, please see the [full Prescribing Information](#).

Supplementary Classification Codes

Supplementary classification codes permit the reporting of circumstances and conditions that impact the disease or injury. When providers use supplementary codes, they should also report a diagnosis code from one of the main chapters of the ICD-10-CM coding manual, indicating the nature of the condition.

Below is a list of ICD-10-CM supplementary classification codes that may be reasonably related to a diagnosis within the product's approved label. Other codes may be appropriate.

Supplementary Classification Code	Description
T45.1X5	Adverse effect of antineoplastic and immunosuppressive drugs
Z41.8	Encounter for other procedures for purposes other than remedying health state
Z51.11	Encounter for antineoplastic chemotherapy

Healthcare Common Procedure Coding System (HCPCS)

Level II Codes

HCPCS codes are 5-digit alphanumeric codes that are assigned to drugs by the Centers for Medicare & Medicaid Services (CMS). AKYNZEO® oral has been assigned a unique HCPCS code in the "J" series (known as J codes).

If a payer's coverage policy allows for AKYNZEO® capsules to be billed under the medical benefit, the J code will need to be submitted. Report 1 unit of J8655 for AKYNZEO® capsule.

J Code	Description
J8655	Netupitant 300 mg and palonosetron 0.5 mg, oral

National Drug Codes (NDCs)

NDCs help providers identify specific product package sizes. The AKYNZEO® capsules NDCs are listed below.

AKYNZEO® Capsules Package Size	Description
Single-dose capsule: 300 mg netupitant/ 0.5 mg palonosetron	69639-101-01

Most payers require providers to report 11-digit NDCs when reporting a drug on a claim form through the pharmacy benefit. Converting the 10-digit NDC for AKYNZEO® to an 11-digit NDC requires the use of a leading zero in the product code section of the AKYNZEO® NDC (i.e., the middle section).

	10-digit NDC	11-digit NDC
Example NDC	AAAAA-BBB-CC	AAAAA-0BBB-CC
AKYNZEO® NDC	62856-796-01	69639-0101-01

We recommend verifying a payer's coding and coverage policies prior to administration of AKYNZEO®. The Helsinn Cares Program can provide information relating to payer-specific coverage policies and billing requirements: **1-84HELINN-U (1-844-357-4668, select prompt 2).**



AKYNZEO® is a registered trademark of Helsinn Healthcare SA, Switzerland, distributed and marketed by Helsinn Therapeutics (U.S.), Inc. under license.

©2018 Helsinn Therapeutics (U.S.), Inc. All rights reserved. V-AKYN-US-0262 05/2018

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

- Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT₃ receptor antagonists.
- Serotonin syndrome has been reported with 5-HT₃ receptor antagonists alone but particularly with concomitant use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO is used concomitantly with other serotonergic drugs.

Adverse Reactions

- Most common adverse reactions for AKYNZEO capsules and injection: headache, asthenia, dyspepsia, fatigue, constipation and erythema

Drug Interactions

- Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO. The inhibitory effect on CYP3A4 can last for multiple days
 - Dexamethasone doses should be reduced when given with AKYNZEO. A more than two-fold increase in the systemic exposure of dexamethasone was observed 4 days after a single dose of netupitant or a single infusion of fosnetupitant
 - Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO. When administered with netupitant, the systemic exposure to midazolam was significantly increased
- Avoid concomitant use of AKYNZEO in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO

Use in Specific Populations

- Avoid use of AKYNZEO in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease
- Avoid use in pregnancy, limited data is available, may cause fetal harm

For more information about AKYNZEO please see the [full Prescribing Information](#).

Reference: 1. Akynzeo® [package insert]. Iselin, NJ: Helsinn Therapeutics (U.S.), Inc; 2018.

